Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients - Pfizer (NYSE:

Read Also: Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study Pfizer Inc.

(NYSE:PFE) on Monday reported mixed topline results from its Phase 3 SigVie-002 trial of investigational antibody-drug conjugate sigvotatug vedotin in previously treated advanced non-squamous non-small cell lung cancer (NSCLC).

While the study missed its primary overall survival endpoint in the broader patient population, it showed encouraging signals in second-line patients.

SigVie-002 Falls Short On Overall Survival Endpoint The SigVie-002 study enrolled adults with locally advanced, unresectable, or metastatic non-squamous NSCLC who had received one or more prior lines of therapy.

According to Pfizer, sigvotatug vedotin did not achieve a statistically significant improvement in overall survival compared with the chemotherapy drug docetaxel across the overall study population.